<p>温和的股价反应表明，<strong>碧迪医疗</strong>（NYSE:BDX）强劲的收益并没有带来任何惊喜。我们的分析表明，投资者可能错过了一些有前景的细节。</p>
<p>人工智能即将改变医疗保健。这 20 只股票正在从早期诊断到药物发现等各个方面进行工作。最棒的是——它们的市值都在 100 亿美元以下——现在仍然有机会提前布局。</p>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/103678-earnings-and-revenue-history-1-dark-2/1779215758002?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/103678-earnings-and-revenue-history-1-dark-2/1779215758002"/></p>
<p>NYSE:BDX 收益和收入历史 2026 年 5 月 19 日</p>
<h2>非常规项目如何影响利润？</h2>
<p>重要的是，我们的数据表明，碧迪医疗的利润因非常规项目在过去一年中减少了 13 亿美元。看到非常规项目导致公司利润下降并不理想，但从积极的一面看，情况可能会比预期更快改善。当我们分析全球绝大多数上市公司时，我们发现显著的非常规项目通常不会重复。这并不令人惊讶，因为这些项目被视为非常规。如果碧迪医疗不再出现这些非常规费用，那么在其他条件相同的情况下，我们预计其利润在未来一年将会增加。</p>
<p>这可能会让你想知道分析师对未来盈利能力的预测。幸运的是，你可以点击这里查看基于他们估计的未来盈利能力的互动图表。</p>
<h2>我们对碧迪医疗利润表现的看法</h2>
<p>非常规项目（费用）在过去一年中削弱了碧迪医疗的收益，但我们可能会在明年看到改善。基于这一观察，我们认为碧迪医疗的法定利润实际上低估了其盈利潜力！此外，其每股收益在过去三年中以每年 5.7% 的速度增长。当然，我们在分析其收益时仅仅是触及了表面；还可以考虑利润率、预测增长和投资回报等其他因素。如果你想更深入地了解碧迪医疗，你还需要关注它目前面临的风险。在投资风险方面，<strong>我们已经识别出碧迪医疗的两个警示信号</strong>，理解这些信号应该是你投资过程的一部分。</p>
<p>今天我们聚焦于一个单一的数据点，以更好地理解碧迪医疗的利润性质。但如果你能够专注于细节，总会有更多的发现。有些人认为高股本回报率是优质企业的良好标志。虽然这可能需要你进行一些研究，但你可能会发现这份 <strong>免费</strong> 的高股本回报率公司集合，或者这份拥有显著内部持股的股票名单对你有帮助。</p>
<h3>估值是复杂的，但我们在这里为你简化。</h3>
<p>通过我们的详细分析，发现碧迪医疗是否可能被低估或高估，分析内容包括 <strong>公允价值估计、潜在风险、股息、内部交易及其财务状况。</strong></p>
<p>获取免费分析</p>

碧迪医疗

美国医药设备 ETF - iShares

标普健康医疗设备 ETF - SPDR

<p>贝克顿·迪金森（NYSE:BDX）强劲的收益并未令投资者感到意外，导致股价反应平淡。去年，异常支出使利润减少了 13 亿美元，但分析师表示这些支出可能不会再次出现，暗示未来可能会有利润增长。该公司的每股收益在过去三年中以每年 5.7% 的速度增长，尽管已识别出两个投资风险。建议进一步分析以评估贝克顿·迪金森的估值和财务状况</p>

<p>The subdued stock price reaction suggests that <strong>Becton, Dickinson and Company's</strong> (NYSE:BDX) strong earnings didn't offer any surprises. Our analysis suggests that investors might be missing some promising details.</p>
<div class="lb-trans"><p>温和的股价反应表明，<strong>碧迪医疗</strong>（NYSE:BDX）强劲的收益并没有带来任何惊喜。我们的分析表明，投资者可能错过了一些有前景的细节。</p>
</div><p>AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.</p>
<div class="lb-trans"><p>人工智能即将改变医疗保健。这 20 只股票正在从早期诊断到药物发现等各个方面进行工作。最棒的是——它们的市值都在 100 亿美元以下——现在仍然有机会提前布局。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/103678-earnings-and-revenue-history-1-dark-2/1779215758002" alt="" original-src="https://images.simplywall.st/asset/chart/103678-earnings-and-revenue-history-1-dark-2/1779215758002"/></p>
<p>NYSE:BDX Earnings and Revenue History May 19th 2026</p>
<div class="lb-trans"><p>NYSE:BDX 收益和收入历史 2026 年 5 月 19 日</p>
</div><h2>How Do Unusual Items Influence Profit?</h2>
<div class="lb-trans"><h2>非常规项目如何影响利润？</h2>
</div><p>Importantly, our data indicates that Becton Dickinson's profit was reduced by US$1.3b, due to unusual items, over the last year. It's never great to see unusual items costing the company profits, but on the upside, things might improve sooner rather than later. When we analysed the vast majority of listed companies worldwide, we found that significant unusual items are often not repeated. And that's hardly a surprise given these line items are considered unusual. If Becton Dickinson doesn't see those unusual expenses repeat, then all else being equal we'd expect its profit to increase over the coming year.</p>
<div class="lb-trans"><p>重要的是，我们的数据表明，碧迪医疗的利润因非常规项目在过去一年中减少了 13 亿美元。看到非常规项目导致公司利润下降并不理想，但从积极的一面看，情况可能会比预期更快改善。当我们分析全球绝大多数上市公司时，我们发现显著的非常规项目通常不会重复。这并不令人惊讶，因为这些项目被视为非常规。如果碧迪医疗不再出现这些非常规费用，那么在其他条件相同的情况下，我们预计其利润在未来一年将会增加。</p>
</div><p>That might leave you wondering what analysts are forecasting in terms of future profitability. Luckily, you can click here to see an interactive graph depicting future profitability, based on their estimates.</p>
<div class="lb-trans"><p>这可能会让你想知道分析师对未来盈利能力的预测。幸运的是，你可以点击这里查看基于他们估计的未来盈利能力的互动图表。</p>
</div><h2>Our Take On Becton Dickinson's Profit Performance</h2>
<div class="lb-trans"><h2>我们对碧迪医疗利润表现的看法</h2>
</div><p>Unusual items (expenses) detracted from Becton Dickinson's earnings over the last year, but we might see an improvement next year. Based on this observation, we consider it likely that Becton Dickinson's statutory profit actually understates its earnings potential! And on top of that, its earnings per share have grown at 5.7% per year over the last three years. Of course, we've only just scratched the surface when it comes to analysing its earnings; one could also consider margins, forecast growth, and return on investment, among other factors. If you want to do dive deeper into Becton Dickinson, you'd also look into what risks it is currently facing. In terms of investment risks, <strong>we've identified 2 warning signs</strong> with Becton Dickinson, and understanding them should be part of your investment process.</p>
<div class="lb-trans"><p>非常规项目（费用）在过去一年中削弱了碧迪医疗的收益，但我们可能会在明年看到改善。基于这一观察，我们认为碧迪医疗的法定利润实际上低估了其盈利潜力！此外，其每股收益在过去三年中以每年 5.7% 的速度增长。当然，我们在分析其收益时仅仅是触及了表面；还可以考虑利润率、预测增长和投资回报等其他因素。如果你想更深入地了解碧迪医疗，你还需要关注它目前面临的风险。在投资风险方面，<strong>我们已经识别出碧迪医疗的两个警示信号</strong>，理解这些信号应该是你投资过程的一部分。</p>
</div><p>Today we've zoomed in on a single data point to better understand the nature of Becton Dickinson's profit. But there is always more to discover if you are capable of focussing your mind on minutiae. Some people consider a high return on equity to be a good sign of a quality business. While it might take a little research on your behalf, you may find this <strong>free</strong> collection of companies boasting high return on equity, or this list of stocks with significant insider holdings to be useful.</p>
<div class="lb-trans"><p>今天我们聚焦于一个单一的数据点，以更好地理解碧迪医疗的利润性质。但如果你能够专注于细节，总会有更多的发现。有些人认为高股本回报率是优质企业的良好标志。虽然这可能需要你进行一些研究，但你可能会发现这份 <strong>免费</strong> 的高股本回报率公司集合，或者这份拥有显著内部持股的股票名单对你有帮助。</p>
</div><h3>Valuation is complex, but we're here to simplify it.</h3>
<div class="lb-trans"><h3>估值是复杂的，但我们在这里为你简化。</h3>
</div><p>Discover if Becton Dickinson might be undervalued or overvalued with our detailed analysis, featuring <strong>fair value estimates, potential risks, dividends, insider trades, and its financial condition.</strong></p>
<div class="lb-trans"><p>通过我们的详细分析，发现碧迪医疗是否可能被低估或高估，分析内容包括 <strong>公允价值估计、潜在风险、股息、内部交易及其财务状况。</strong></p>
</div><p>Access Free Analysis</p>
<div class="lb-trans"><p>获取免费分析</p>
</div>

碧迪医疗（NYSE:BDX）的收益质量将令股东们感到满意